Expertise in

conditions

Dr. Thomas J. Reid

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

MERCYHEALTH

Mercy Health Physicians Springfield Specialty Care LLC

148 W N St,

Springfield, OH

Clinical Trials:Currently Recruiting for 4 Trials

Accepting New Patients

Offers Telehealth

Expertise in

conditions

MERCYHEALTH

Mercy Health Physicians Springfield Specialty Care LLC

148 W N St,

Springfield, OH

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Reid is a Gynecologic Oncologist and an Oncologist in Springfield, Ohio. Dr. Reid is highly rated in 30 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy. Dr. Reid is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 95 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gynecologic Oncology

Oncology

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OH

Hospital Affiliations

Kettering Health Troy

Soin Medical Center

Miami Valley Hospital

Kettering Health Main Campus

Kettering Health Dayton

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Buckeye Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

CareSource

Cigna

Devoted Health

MEDICARE MAPD
OTHER MEDICARE

First Health

INSURANCE PLAN
MEDICARE PDP
PPO

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medical Health

Medical Mutual

MetLife

Oscar

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 15 Less Insurance Carriers -

Locations

MERCY HEALTH PHYSICIANS SPRINGFIELD SPECIALTY CARE LLC
148 W N St, Springfield, OH 45504

Call: 937-323-5001

Other Locations

MERCY HEALTH PHYSICIANS SPRINGFIELD SPECIALTY CARE LLC
900 Scioto St, Suite 1, Urbana, OH 43078

Call: 937-717-4884

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

95 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Procedure, Other

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Enrollment Status: Recruiting

Publish Date: March 13, 2025

Intervention Type: Drug

Study Drug: Screening Platform

Study Phase: Phase 2/Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride

Study Phase: Phase 3

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate

Study Phase: Phase 2

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride

Study Phase: Phase 2/Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab

Study Phase: Phase 2

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Lenalidomide

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Other, Radiation, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Other

Study Drug: Pazopanib Hydrochloride

Study Phase: Phase 3

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Enrollment Status: Active_not_recruiting

Publish Date: September 16, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride

Study Phase: Phase 2/Phase 3

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Drug

Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed

Study Phase: Phase 3

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Drug

Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide

Study Phase: Phase 3

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer

Enrollment Status: Completed

Publish Date: September 05, 2025

Intervention Type: Procedure

Study Phase: Phase 3

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab

Study Phase: Phase 2

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 13, 2025

Intervention Type: Other, Drug

Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide

Study Phase: Phase 2/Phase 3

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: July 30, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: July 17, 2025

Intervention Type: Other, Drug

Study Drug: Naloxegol

Study Phase: Phase 2

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

Enrollment Status: Completed

Publish Date: May 23, 2025

Intervention Type: Other, Radiation, Drug

Study Drug: Cisplatin

Study Phase: Phase 3

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Enrollment Status: Completed

Publish Date: April 06, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Enrollment Status: Completed

Publish Date: March 17, 2025

Intervention Type: Drug

Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed

Study Phase: Phase 2

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Enrollment Status: Completed

Publish Date: February 13, 2025

Intervention Type: Drug

Study Drugs: Fulvestrant, Alpelisib

Study Phase: Phase 3

Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias

Enrollment Status: Completed

Publish Date: January 28, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

Enrollment Status: Terminated

Publish Date: January 24, 2025

Intervention Type: Biological, Drug

Study Drugs: HSPPC-96, Bevacizumab

Study Phase: Phase 2

Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study

Enrollment Status: Terminated

Publish Date: January 20, 2025

Intervention Type: Drug, Radiation, Procedure

Study Phase: Phase 2

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 17, 2025

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502

Enrollment Status: Terminated

Publish Date: January 16, 2025

Intervention Type: Procedure

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

Enrollment Status: Completed

Publish Date: January 13, 2025

Intervention Type: Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

View 46 Less Clinical Trials

21 Total Publications

Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.

Journal: Gynecologic oncology

Published: March 17, 2024

View All 21 Publications

Similar Doctors

Expertise in

conditions

Dr. David E. Cohn

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Expertise in

conditions

Dr. David E. Cohn

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Osu Gyn And Ob Consultants, LLC

460 W 10th Ave,

Columbus, OH

(42.3 miles away)

614-293-7642

Languages Spoken:

English, Spanish

See accepted insurances

Accepting New Patients

Offers Telehealth

David Cohn is a Gynecologic Oncologist and an Oncologist in Columbus, Ohio. Dr. Cohn is highly rated in 20 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Adult Soft Tissue Sarcoma, Hysterectomy, and Salpingo-Oophorectomy. Dr. Cohn is currently accepting new patients.

Expertise in

conditions

Dr. Christa I. Nagel

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Expertise in

conditions

Dr. Christa I. Nagel

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Osu Gyn And Ob Consultants, LLC

3651 Ridge Mill Dr,

Hilliard, OH

(37.7 miles away)

614-293-3873

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Christa Nagel is a Gynecologic Oncologist and an Oncologist in Hilliard, Ohio. Dr. Nagel is highly rated in 14 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Vulvectomy. Dr. Nagel is currently accepting new patients.

Expertise in

conditions

Dr. Larry J. Copeland

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Expertise in

conditions

Dr. Larry J. Copeland

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Osu Gyn And Ob Consultants, LLC

3651 Ridge Mill Dr,

Hilliard, OH

(37.7 miles away)

614-293-3873

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Larry Copeland is a Gynecologic Oncologist and an Oncologist in Hilliard, Ohio. Dr. Copeland is highly rated in 16 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Vulvectomy. Dr. Copeland is currently accepting new patients.

VIEW MORE Gynecologic Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reid's expertise for a condition

ConditionClose